# Venetoclax After TKI to Target Persisting Stem Cells in CML

> **NCT05701215** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Ernst, PD Dr. med.** · enrollment: 10 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05701215
- **Lead sponsor:** Thomas Ernst, PD Dr. med.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701215, "Venetoclax After TKI to Target Persisting Stem Cells in CML". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05701215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*